Duality Biologics and GSK Enter into Exclusive License Agreement to Co-Develop Novel Antibody-Drug Conjugate DB-1324
DualityBio
Innovative Molecular Type Drug Developer
GSK
Pharmaceutical R&D Manufacturer
According to the agreement, GSK will obtain exclusive rights globally (excluding mainland China, Hong Kong, and Macao) to advance the research, development, and commercialization process of this ADC drug.
DB-1324 is an innovative ADC molecule developed based on the Duality Immune Toxin Antibody Conjugates (DITAC) platform, which is unique to DualityBio and has been clinically validated. It is currently still in the preclinical development stage, and its research direction may focus on gastrointestinal (GI) cancers.。There are still many unmet clinical needs for patients with gastrointestinal (GI) cancers globally. GI cancer patients account for 35% of all cancer-related deaths and approximately 26% of global cancer incidence. Additionally, this ADC drug has the potential to be used in combination with multiple oncology products from GSK, thereby strategically complementing GSK's oncology portfolio.
According to the terms of the agreement, GSK willAn upfront payment of $30 million...and other pre-exercise milestone payments to obtain an exclusive license for the development and commercialization of DB-1324 worldwide (excluding mainland China, Hong Kong, and Macao). If GSK exercises the license option, DualityBio will receive an option exercise fee and subsequent milestone payments at different stages of development, regulatory registration, and commercialization, which could reach up to 975 million US dollars. Upon successful commercialization, GSK will pay tiered royalties on global net sales (excluding mainland China, Hong Kong, and Macao) at varying percentages and will also receive royalties from net sales in mainland China, Hong Kong, and Macao.
Previous Review
